Sarcoma News and Research

RSS

Surgeons use 3D printed implant in patient diagnosed with chest wall sarcoma

After being diagnosed with a chest wall sarcoma, a 54-year-old Spanish man's surgical team made the decision to remove his sternum and a portion of his rib cage and replace it with an implant.

14 Sep 2015

American Income Life donates $10,000 to Sarcoma Foundation of America

American Income Life Insurance Company, headquartered in Waco, TX, in partnership with State General Agents Tom Williams and David Zophin, donated $10,000 to the Sarcoma Foundation of America (South Florida Chapter) as part of the Company's Closer to the Heart program of charitable giving.

14 Sep 2015

CHAM, AECC receive $1.3 million NCI grant to advance more effective bone cancer treatments for children

The Children's Hospital at Montefiore and the NCI-designated Albert Einstein Cancer Center today announced receipt of $1.3 million grant from the National Cancer Institute, part of the National Institutes of Health.

9 Sep 2015

Adaptimmune doses first patient in expanded Phase I/II trial of T-cell therapy for synovial sarcoma

Adaptimmune Therapeutics plc, a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that the first patient has been dosed in its expanded Phase I/II trial of its affinity enhanced T-cell receptor therapeutic targeting the NY-ESO-1 cancer antigen in synovial sarcoma patients.

3 Sep 2015

Discovery could open up door for cancer research and treatment

Florida State University researchers have taken a big step forward in the fight against cancer with a discovery that could open up the door for new research and treatment options.

28 Aug 2015

New NCCN Guidelines for Patients and NCCN Quick Guide for Kidney Cancer published

Kidney Cancer is among the 10 most diagnosed cancers in both men and women in the United States, and it is estimated that more than 60,000 new cases of kidney cancer will be diagnosed in 2015.

27 Aug 2015

Landmark 'basket study' shows efficacy of vemurafenib in multiple nonmelanoma BRAFV600-mutated cancers

Researchers from Memorial Sloan Kettering Cancer Center have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients' tumors rather than where their cancer originated.

20 Aug 2015

Organ transplant recipients more likely to develop melanoma

Organ transplant recipients are twice as likely to develop melanoma as people who do not undergo a transplant, and three times more likely to die of the dangerous skin cancer, suggests new research led by a Johns Hopkins Bloomberg School of Public Health student.

14 Aug 2015

Researchers show how realistic environments affect growth of cancer tumors in bones

Researchers at Rice University and University of Texas MD Anderson Cancer Center have developed a way to mimic the conditions under which cancer tumors grow in bones.

6 Aug 2015

CRI commits $29.3 million in new funds to accelerate development of cancer immunotherapies

The Cancer Research Institute, a nonprofit organization dedicated to fueling the discovery and development of immunotherapies for all forms of cancer, announced that it has committed more than $29.3 million in new funds to accelerate cancer immunology research and cancer immunotherapy clinical development in the United States, Australia, Canada, France, Sweden, Switzerland, and The Netherlands.

5 Aug 2015

Daiichi Sankyo, Plexxikon’s Phase 1 trial shows PLX3397 induced prolonged tumor regression in TGCT patients

Daiichi Sankyo Europe and Plexxikon Inc., a member of the Daiichi Sankyo Group, announced today that The New England Journal of Medicine published clinical trial results demonstrating that the investigational drug, PLX3397, an oral targeted CSF-1R inhibitor, induced prolonged tumor regressions in most patients with tenosynovial giant cell tumor, a rare, locally aggressive neoplasm of the joint or tendon sheath.

31 Jul 2015

Research brief provides clinical validation of LOXO-101 Phase 1 trial for treatment of TRK fusion cancer

The University of Colorado Cancer Center and Loxo Oncology, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of targeted cancer therapies, today announced the publication of a research brief in the online edition of the journal Cancer Discovery, describing the first patient with a tropomyosin receptor kinase fusion cancer enrolled in the Phase 1 dose escalation trial of LOXO-101, the only selective TRK inhibitor in clinical development.

28 Jul 2015

LMU researchers reveal role of mutations in development of Ewing's sarcoma

Researchers from Ludwig-Maximilians-Universitaet in Munich have elucidated at the molecular level how an otherwise innocuous inherited mutation that is quite common in European populations interacts with a spontaneous somatic mutation to promote the development of Ewing's sarcoma.

28 Jul 2015

Research brief describes enrollment of first patient with TRK fusion cancer in LOXO-101 Phase 1 trial

The University of Colorado Cancer Center and Loxo Oncology, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of targeted cancer therapies, today announced the publication of a research brief in the online edition of the journal Cancer Discovery, describing the first patient with a tropomyosin receptor kinase (TRK) fusion cancer enrolled in the Phase 1 dose escalation trial of LOXO-101, the only selective TRK inhibitor in clinical development.

28 Jul 2015

UofL conducts Phase I research study for children with relapsed tumors

Zach feels "pretty good." Sam wants to be "done with shots!" And Tyler finds it helps to "just keep thinking that at least I'm getting out of school." They are normal boys who had normal lives until cancer came into the picture. All have faced the disease for two years or more, with surgeries, chemotherapy and radiation treatments. All were diagnosed with various malignant solid tumors, went into remission and then relapsed.

17 Jul 2015

FDA accepts Blueprint Medicines' IND applications to start Phase 1 clinical trials for two drug candidates

Blueprint Medicines today announced that the U.S. Food and Drug Administration accepted the Company's Investigational New Drug (IND) applications to begin Phase 1 clinical trials for its two lead drug candidates: BLU-554 for the treatment of advanced hepatocellular carcinoma (HCC) and cholangiocarcinoma, and BLU-285 for unresectable, treatment-resistant gastrointestinal stromal tumor (GIST).

13 Jul 2015

Four young scientists named recipients of Damon Runyon-Sohn Pediatric Cancer Research Fellowship Award

The Damon Runyon Cancer Research Foundation has named four outstanding young scientists as recipients of the prestigious Damon Runyon-Sohn Pediatric Cancer Research Fellowship Award, committing nearly $875,000 to help address a critical shortage of funding for pediatric cancer research.

10 Jul 2015

New research identifies potential treatment for primary effusion lymphoma

New research from the University of Southern California Norris Comprehensive Cancer Center has identified a potential treatment for a rare but previously incurable form of lymphoma that is observed primarily in patients with HIV/AIDS infection.

8 Jul 2015

New therapeutic alternative found for children suffering from Ewing's sarcoma

A research consortium made up of the Virgen del Rocio hospital in Seville, Sant Joan de Deu and the Bellvitge Biomedical Research Institute in Barcelona, has found a new therapeutic alternative for children who suffer from a malignant pediatric tumor bone and soft tissue called Ewing's sarcoma.

7 Jul 2015

Pazopanib improves survival in soft tissue sarcoma patients without impairment of health-related quality of life

Results of EORTC trial 62072 appearing in Cancer show that in patients with soft tissue sarcoma, whose disease had progressed during or after prior chemotherapy, pazopanib improved progression-free survival but did not change health-related quality of life. This observed improvement in progression-free survival without impairment of health-related quality of life was considered a meaningful result.

7 Jul 2015

Sarcoma News and Research

Surgeons use 3D printed implant in patient diagnosed with chest wall sarcoma

American Income Life donates $10,000 to Sarcoma Foundation of America

CHAM, AECC receive $1.3 million NCI grant to advance more effective bone cancer treatments for children

Adaptimmune doses first patient in expanded Phase I/II trial of T-cell therapy for synovial sarcoma

Discovery could open up door for cancer research and treatment

New NCCN Guidelines for Patients and NCCN Quick Guide for Kidney Cancer published

Landmark 'basket study' shows efficacy of vemurafenib in multiple nonmelanoma BRAFV600-mutated cancers

Organ transplant recipients more likely to develop melanoma

Researchers show how realistic environments affect growth of cancer tumors in bones

CRI commits $29.3 million in new funds to accelerate development of cancer immunotherapies

Daiichi Sankyo, Plexxikon’s Phase 1 trial shows PLX3397 induced prolonged tumor regression in TGCT patients

Research brief provides clinical validation of LOXO-101 Phase 1 trial for treatment of TRK fusion cancer

LMU researchers reveal role of mutations in development of Ewing's sarcoma

Research brief describes enrollment of first patient with TRK fusion cancer in LOXO-101 Phase 1 trial

UofL conducts Phase I research study for children with relapsed tumors

FDA accepts Blueprint Medicines' IND applications to start Phase 1 clinical trials for two drug candidates

Four young scientists named recipients of Damon Runyon-Sohn Pediatric Cancer Research Fellowship Award

New research identifies potential treatment for primary effusion lymphoma

New therapeutic alternative found for children suffering from Ewing's sarcoma

Pazopanib improves survival in soft tissue sarcoma patients without impairment of health-related quality of life

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News